Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial OF Oxaliplatin and Gemcitabine With Bevacizumab in Advanced Non-Small Cell Lung Cancer
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown favorable results in advanced NSCLC. This study will add bevacizumab to oxaliplatin and gemcitabine as first line treatment in patients with Stage IIIB and IV NSCLC.
STUDY OBJECTIVES:
Primary:
To determine the overall time to progression of the combination regimen of Gemcitabine,
Oxaliplatin and Bevacizumab as first-line treatment in patients with Stage IIIB and IV
non-small cell lung cancer.
Secondary
- To determine the overall response rate
- To determine the overall survival.
- To determine the toxicity of Gemcitabine, Oxaliplatin given in combination with
Bevacizumab
ELIGIBILITY CRITERIA
1. Patients must have histologically or cytologically confirmed non-small cell lung cancer
EXCEPT squamous cell carcinoma. Mixed tumors will be categorized by the predominant
cell type unless small cell elements are present in which case the patient is
ineligible. Cytologic or histologic elements can be established on metastatic tumor
aspirates or biopsy.
2. Patients must have advanced NSCLC (Stage IIIB with malignant pleural effusion or Stage
IV or recurrent disease).
3. Patients must have measurable disease (as defined in Section 13.0).
4. ECOG performance status 0 or 1.
5. Patients must not have known CNS metastases. Brain imaging is required within 4 weeks
prior to study entry.
6. No prior systemic treatment for advanced NSCLC is permitted. Prior treatment for
early-stage disease (adjuvant) or for locally-advanced Stage III disease is allowed if
completed at least 12 months prior to registration.
7. Required laboratory values (obtained 2 weeks prior to registration):
7.1 ANC > 1500/mm³. 7.2 Platelets > 100,000/mm³. 7.3 Total Bilirubin < 1.5 mg/dl. 7.4
Transaminases < 5 x ULN.
8. Patients must have adequate renal function as determined by the following tests within
2 weeks prior to registration.
8.1 Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN), AND
Urinalysis < 1+ protein*
* Patients discovered to have >1+ proteinuria at baseline must undergo a 24-hour urine
collection. This must be an adequate collection and must demonstrate <1g of protein/24
hr to allow participation in the study.
9. Patients must be 18 years or older.
10. Pregnant and lactating women are excluded from the study because the agents used in
this study may be teratogenic to a fetus and there is no information on the excretion
of the agents or their metabolites into breast milk. A negative urine or serum
pregnancy test required for women of childbearing potential.
11. Women of childbearing potential and sexually active males must agree to use an accepted
and effective method of contraception (hormonal or barrier methods, abstinence) prior
to study entry and for the duration of the study.
12. Patients treated with radiation therapy must have adverse events from therapy resolved
to grade 2 or less following completion of treatment.
13. Patients must not have ongoing or active infection, symptomatic congestive heart
failure, cerebrovascular accident within 12 months, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
14. Patients must have no deep vein thrombosis or pulmonary embolus within one year of
registration and no ongoing need for full-dose oral or parenteral anticoagulation. Low
dose coumadin (1mg) for maintenance of catheter patency or daily prophylactic aspirin
is allowed.
15. Patients with history of hypertension must be well-controlled (defined as a blood
pressure of >160 mmHg systolic and/or > 110 mmHg diastolic) on a stable regimen of
anti-hypertensive therapy.
16. Patients must not have serious non-healing wound ulcer, or bone fracture, or major
surgical procedure within 3 weeks prior to starting treatment.
17. Patients with a history of gross hemoptysis (defined as bright red blood of a ½
teaspoon or more) will be excluded from this trial
18. No prior malignancy is allowed except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
been disease-free for five years
TREATMENT PLAN Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by
Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90*
minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be
re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four
cycles or until progression or unacceptable toxicity.
Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:
Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |